Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Aura Biosciences Q3 2026 Results: Net Loss of $32.1M, Loss Widens

Aura Biosciences reported a significant increase in net loss to $111.4 million for the nine months ended September 30, 2026, driven by rising R&D and G&A expenses. Despite the loss, the company strengthened its balance sheet through a follow-on offering, ending the period with $303.1 million in current assets compared to $149.7 million at the end of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-32.0-26.1
Net income-32.1-26.1
EPS (diluted, $ a share)$-0.29$-0.40

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: AURA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Aura Biosciences, Inc.: key numbers

Share price
$7.22Close, Nov 16
Market cap
$751M
Shares outstanding
104.07MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Aura Biosciences, Inc.

All →
7:06 AM ET 8-K
Financial Results

Aura Biosciences Financial Results

Aura Biosciences reported Q3 2026 financial results and provided a clinical update on its Phase 3 CoMpass trial for bel-sar, which remains on track for topline data in 2H 2027. The company also established a new manufacturing relationship with a CDMO to secure designated capacity for bel-sar and confirmed its cash runway extends into the first half of 2029.

“During the third quarter, we continued to execute against our focused ocular oncology strategy and build the operational capabilities needed for our next stage of development. With all treatment visits completed in the CoMpass trial, our team is focused on ensuring excellence in all elements of the bel-sar program as we advance toward topline pivotal data in the second half of next year and position bel-sar as the first potential vision-preserving front-line therapy for early choroidal melanoma.”

Natalie Holles, Chief Executive Officer of Aura Biosciences

“We are very pleased to enter this new CDMO relationship, which we believe positions bel-sar for regulatory and commercial success as we advance toward topline data and completion of the CoMpass study. Designated capacity is intended to provide us with long-term control over our production scheduling, and we look forward to working with our new partner to advance this important element of the bel-sar program.”

Susan Abu-Absi, Ph.D., Chief Operating Officer of Aura Biosciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.